People engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia: A qualitative study

被引:2
|
作者
Conway, Anna [1 ,2 ]
Treloar, Carla [2 ]
Crawford, Sione [3 ]
Grebely, Jason [1 ]
Marshall, Alison D. [1 ,2 ]
机构
[1] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia
[2] UNSW Sydney, Ctr Social Res Hlth, Sydney, NSW, Australia
[3] Harm Reduct Victoria, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
Big Event; counterpublic; peers; practises of care; substance use; HEPATITIS-C; HEALTH; BARRIERS;
D O I
10.1111/dar.13531
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction People receiving opioid agonist treatment (OAT) are at higher risk of comorbidities, poverty and discrimination, which Big Events like the COVID-19 pandemic may exacerbate. The behaviours of people receiving OAT do not always align with normative behaviours as conceived by ruling institutions and laws, and so the group becomes a counterpublic, not imagined in mainstream public discourse. The aim of this study was to understand how people receiving OAT, as a counterpublic, implemented practises of care to mitigate negative health outcomes during COVID-19. Methods Participants were recruited via eight peer-led organisations across Australia. In-depth, semi-structured interviews were completed between August and December 2020 with 40 people receiving OAT. The analysis centres practises of care, allowing interactions that influence the health of participants, to be understood in their unique contexts. Results Aspects of the COVID-19 state response were designed for an idealised public, demonstrated by the increased policing that accompanied enforcement of restrictions which was detrimental to the wellbeing of people receiving OAT. Counterpublic health strategies employed by people receiving OAT were disrupted, but participants were often able to adapt to the changing context. Discussion and Conclusion This study elucidates how practises of care among people receiving OAT are enacted and disrupted during a Big Event, with implications beyond the COVID-19 pandemic for future Big Events. The study findings evidence the need for policies that mitigate the impact of Big Events such as supporting re-groupment within the counterpublic, legitimising counterpublic health strategies and stopping the criminalisation of people who use drugs.
引用
收藏
页码:203 / 212
页数:10
相关论文
共 50 条
  • [1] Opioid Agonist Treatment Modifications During COVID-19 Pandemic
    Sproule, Beth
    Stovel, Jessica
    Saragosa, Julia
    Huynh, Helen
    Di Paola, Francesca
    Brands, Bruna
    Zhang, Maria
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [2] Experiences of people with opioid use disorder during the COVID-19 pandemic: A qualitative study
    Galarneau, Lexis R.
    Hilburt, Jesse
    O'Neill, Zoe R.
    Buxton, Jane A.
    Scheuermeyer, Frank X.
    Dong, Kathryn
    Kaczorowski, Janusz
    Orkin, Aaron M.
    Barbic, Skye Pamela
    Bath, Misty
    Moe, Jessica
    Miles, Isabelle
    Tobin, Dianne
    Grier, Sherry
    Garrod, Emma
    Kestler, Andrew
    PLOS ONE, 2021, 16 (07):
  • [3] Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia
    Lintzeris, Nicholas
    Deacon, Rachel M.
    Hayes, Victoria
    Cowan, Tracy
    Mills, Llewellyn
    Parvaresh, Laila
    Dodds, Lucy Harvey
    Jansen, Louisa
    Dojcinovic, Raelene
    Leung, Man Cho
    Demirkol, Apo
    Finch, Therese
    Mammen, Kristie
    DRUG AND ALCOHOL REVIEW, 2022, 41 (05) : 1009 - 1019
  • [4] Commentary on 'Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia'
    Steele, Maureen
    Acheson, Liam S.
    DRUG AND ALCOHOL REVIEW, 2022, 41 (05) : 1020 - 1022
  • [5] "You'll come in and dose even in a global pandemic": A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic
    Conway, Anna
    Treloar, Carla
    Crawford, Sione
    Degenhardt, Louisa
    Dore, Gregory J.
    Farrell, Michael
    Hayllar, Jeremy
    Grebely, Jason
    Marshall, Alison D.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2023, 114
  • [6] Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study
    Scott, Gemma
    Turner, Sophie
    Lowry, Natalie
    Hodge, Annette
    Ashraf, Waniya
    McClean, Katie
    Kelleher, Mike
    Mitcheson, Luke
    Marsden, John
    BMJ OPEN, 2023, 13 (03):
  • [7] Buprenorphine Opioid Treatment During the COVID-19 Pandemic
    Luigi, Mimosa
    Luo, Michael
    Maes, Etienne J. P.
    JAMA INTERNAL MEDICINE, 2021, 181 (08) : 1135 - 1135
  • [8] Factors Associated With Increased Opioid Use During the COVID-19 Pandemic: A Prospective Study of Patients Enrolled in Opioid Agonist Treatment
    Rosic, Tea
    Naji, Leen
    Sanger, Nitika
    Marsh, David C.
    Worster, Andrew
    Thabane, Lehana
    Samaan, Zainab
    JOURNAL OF ADDICTION MEDICINE, 2022, 16 (04) : E257 - E264
  • [9] Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study
    Conway, Anna
    Marshall, Alison D.
    Crawford, Sione
    Hayllar, Jeremy
    Grebely, Jason
    Treloar, Carla
    IMPLEMENTATION SCIENCE, 2023, 18 (01)
  • [10] Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study
    Anna Conway
    Alison D. Marshall
    Sione Crawford
    Jeremy Hayllar
    Jason Grebely
    Carla Treloar
    Implementation Science, 18